Incyte Corporation (INCY)
Incyte Corporation (INCY) Stock Price, Analysis & Data
| Bid | 108.88 |
| Market Cap | 24.36B |
| Revenue (ttm) | 5.82B |
| Net Income (ttm) | 1.61B |
| Beta | 0.77 |
| EPS (ttm) | 7.82 |
| PE Ratio (ttm) | 15.37 |
| Forward PE | 13.53 |
| P/B (ttm) | 3.81 |
| P/S (ttm) | 4.19 |
| Earnings Date | Oct 27, 2026 |
| Ask | 128.49 |
| Volume | 694,313 |
| Avg. Volume (20D) | 1,872,940 |
| Open | 119.02 |
| Previous Close | 120.52 |
| Day's Range | 117.56 - 120.44 |
| 52-Week Range | 81.09 - 132.60 |
| Analyst | Buy |
| Price Target | 120 (-0.13%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About INCY
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJ...
Financial Performance
In 2025, Incyte's revenue was 5.14B, an increase of 21.22% compared to the previous year's 4.24B. Earnings were 1.29B, an increase of 3,844.96%.
Financial StatementsAnalyst Forecast
According to 23 analyst ratings, the average rating for INCY stock is "Buy". The 12-month stock price forecast is 120, which is downside of 0.13% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
